CCXI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ChemoCentryx, Inc.

·2 min read

New York, New York--(Newsfile Corp. - June 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) between November 26, 2019 and May 6, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
http://www.wongesq.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16858&wire=5

Allegations against CCXI include that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

If you suffered a loss in ChemoCentryx you have until July 6, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87502

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting